Range of Treatment Options, Precision-Based Medicine a Focus for Ovarian Cancers

Article

In this clip, Maurie Markman, MD, discusses ovarian cancer as a chronic illness, and an increasing need for precision medicine.

The range of options for treating gynecologic malignancies is expanding with approved targeted agents and a greater focus on maintaining quality of life (QoL). According to Maurie Markman, MD, who has been in the field for decades, the field is moving in a precision-based medicine direction, with an expanding array of options for managing patients.

Within the last few years, 3 FDA-approved PARP inhibitors have altered the way oncologists treat select patients with ovarian cancer. In May 2018, rucaparib (Rubraca) joined niraparib (Zejula) and olaparib (Lynparza) as having maintenance-setting indications for the treatment of patients who are in complete or partial response to platinum-based chemotherapy. Combination therapies that incorporate immunotherapy are also being studied.

In this clip, Markman discusses ovarian cancer as a chronic illness, and the increasing focus on precision medicine.

Related Videos
Pride flags during pride event -- Image credit: ink drop | stock.adobe.com
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
pain management palliative care/Image Credits: © Aleksej - stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
palliative and hospice care/ Image Credits: © David Pereiras - stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
multiple myeloma clinical trial daratumumab/ Image Credits: © Dragana Gordic - stock.adobe.com
multiple myeloma clinical trial/Image Credits: © Studio Romantic - stock.adobe.com
3d rendered illustration of lung cancer 3D illustration - Image credit:  appledesign | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.